Are you Dr. Dalton?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Robert Dalton, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota and Wisconsin. He is affiliated with Mayo Clinic Hospital - Rochester.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1976 - 1978- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1975 - 1976
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1973 - 1975
New York Medical College (Metropolitan)Internship, Internal Medicine, 1970 - 1971- New York Medical CollegeClass of 1970
Certifications & Licensure
MN State Medical License 1973 - 2025
WI State Medical License 1985 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 76 citationsPhase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients Wi...David P. Steensma, Jeff A. Sloan, Shaker R. Dakhil, Robert J. Dalton, S. P. Kahanic
Journal of Clinical Oncology. 2011-01-01 - 122 citationsDiagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) GuidelinesStephen M. Ansell, Robert A. Kyle, Craig B. Reeder, Rafael Fonseca, Joseph R. Mikhael
Mayo Clinic Proceedings. 2010-09-01 - 26 citationsZoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapyStephanie L. Hines, Jeff A. Sloan, Pamela J. Atherton, Edith A. Perez, Shaker R. Dakhil
Breast. 2010-04-01
Grant Support
- Duluth Community Clincial Oncology ProgramNational Cancer Institute2002–2004
